Notice:  As we transition our hotline team back to in-office services, we remain focused on responding to patient inquiries. We kindly ask pharmacies, providers, and their staff to continue to use our Pharmacy and Provider Portals. If you have a question that cannot be answered by visiting the portal, please send an email to grants@healthwellfoundation.org. We appreciate your patience and look forward to serving you. The HealthWell Team

Dismiss alert
By Emily Burke, Ph.D., Director of Instruction, BiotechPrimer.com  |  Mar 11, 2020

Search & Destroy: Chimeric Antigen Receptor T-Cells (CAR-T)

Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.

Close menu